The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.

Massive attack: Galactoside prodrugs have been designed that can be selectively activated by lysosomal β-galactosidase located inside cancer cells expressing a specific tumor-associated receptor. This efficient enzymatic process triggers a potent cytotoxic effect, releasing the potent antimitotic agent MMAE and allowing the destruction of both receptor-positive and surrounding receptor-negative tumor cells.

[1]  F. Guilhot,et al.  Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin. , 2012, Journal of medicinal chemistry.

[2]  S. Sieber,et al.  Duocarmycin analogues target aldehyde dehydrogenase 1 in lung cancer cells. , 2012, Angewandte Chemie.

[3]  J. Muller,et al.  A new cyclopamine glucuronide prodrug with improved kinetics of drug release. , 2011, Organic & biomolecular chemistry.

[4]  L. Tietze,et al.  Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT. , 2011, Current pharmaceutical design.

[5]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[6]  J. Roche,et al.  A Galactosidase‐Responsive “Trojan Horse” for the Selective Targeting of Folate Receptor‐Positive Tumor Cells , 2011, ChemMedChem.

[7]  C. Liu,et al.  The Legumain Protease‐Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity , 2011, ChemMedChem.

[8]  B. Krewer,et al.  Glycosidische Prodrugs hochpotenter difunktioneller Duocarmycin‐Derivate für eine selektive Tumortherapie , 2010 .

[9]  L. Tietze,et al.  Glycosidic prodrugs of highly potent bifunctional duocarmycin derivatives for selective treatment of cancer. , 2010, Angewandte Chemie.

[10]  Stephen C Alley,et al.  Antibody-drug conjugates: targeted drug delivery for cancer. , 2010, Current opinion in chemical biology.

[11]  P. Low,et al.  Folate-targeted therapies for cancer. , 2010, Journal of medicinal chemistry.

[12]  Duxin Sun,et al.  Biodistribution of HuCC49DeltaCH2-beta-galactosidase in colorectal cancer xenograft model. , 2010, International journal of pharmaceutics.

[13]  L. Tietze,et al.  Antibody‐Directed Enzyme Prodrug Therapy: A Promising Approach for a Selective Treatment of Cancer Based on Prodrugs and Monoclonal Antibodies , 2009, Chemical biology & drug design.

[14]  D. Leigh,et al.  Rotaxane-based propeptides: protection and enzymatic release of a bioactive pentapeptide. , 2009, Angewandte Chemie.

[15]  P. Low,et al.  Folate-targeted therapeutic and imaging agents for cancer. , 2009, Current opinion in chemical biology.

[16]  M. Thomas,et al.  Design of self-immolative linkers for tumour-activated prodrug therapy. , 2008, Anti-cancer agents in medicinal chemistry.

[17]  U. Bhadra,et al.  Development of Pyrrolo[2,1‐c][1,4]benzodiazepine β‐Galactoside Prodrugs for Selective Therapy of Cancer by ADEPT and PMT , 2008, ChemMedChem.

[18]  F. Kratz,et al.  Prodrug Strategies in Anticancer Chemotherapy , 2008, ChemMedChem.

[19]  G. Bringmann,et al.  Selective treatment of cancer: synthesis, biological evaluation and structural elucidation of novel analogues of the antibiotic CC-1065 and the duocarmycins. , 2007, Chemistry.

[20]  P. Low,et al.  Characterization of the pH of Folate Receptor-Containing Endosomes and the Rate of Hydrolysis of Internalized Acid-Labile Folate-Drug Conjugates , 2007, Journal of Pharmacology and Experimental Therapeutics.

[21]  J. Roche,et al.  Synthesis and biological evaluation of the suberoylanilide hydroxamic acid (SAHA) beta-glucuronide and beta-galactoside for application in selective prodrug chemotherapy. , 2007, Bioorganic & medicinal chemistry letters.

[22]  D. Ross,et al.  Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49ΔCH2-β-galactosidase conjugates , 2006 .

[23]  P. Low,et al.  Synthesis and activity of a folate peptide camptothecin prodrug. , 2006, Bioorganic & medicinal chemistry letters.

[24]  L. Tietze,et al.  Antitumor‐Wirkstoffe: Entwicklung hochpotenter glycosidischer Duocarmycin‐Analoga für eine selektive Krebstherapie , 2006 .

[25]  L. Tietze,et al.  Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy. , 2006, Angewandte Chemie.

[26]  K. Bagshawe.  Antibody-directed enzyme prodrug therapy (ADEPT) for cancer , 2006, Expert review of anticancer therapy.

[27]  Philip S Low,et al.  Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging , 2006, Proceedings of the National Academy of Sciences.

[28]  P. Senter,et al.  Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates. , 2006, Bioconjugate chemistry.

[29]  Paul J Maddon,et al.  Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen , 2006, Clinical Cancer Research.

[30]  Philip S Low,et al.  Folate receptor-mediated drug targeting: from therapeutics to diagnostics. , 2005, Journal of pharmaceutical sciences.

[31]  P. Low,et al.  Folate receptor-targeted drugs for cancer and inflammatory diseases. , 2004, Advanced drug delivery reviews.

[32]  M. Ratnam,et al.  Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. , 2004, Advanced drug delivery reviews.

[33]  Nico P E Vermeulen,et al.  Enzyme-Catalyzed Activation of Anticancer Prodrugs , 2004, Pharmacological Reviews.

[34]  Damon L. Meyer,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003, Nature Biotechnology.

[35]  Sandra L. Schmid,et al.  Regulated portals of entry into the cell , 2003, Nature.

[36]  L. Tietze,et al.  Synthesis and Biological Evaluation of Novel Analogues and Prodrugs of the Cytotoxic Antibiotic CC-1065 for Selective Cancer Therapy , 2002 .

[37]  L. Tietze,et al.  Proof of principle in the selective treatment of cancer by antibody-directed enzyme prodrug therapy: the development of a highly potent prodrug. , 2002, Angewandte Chemie.

[38]  J. Florent,et al.  Design of selectively activated anticancer prodrugs: elimination and cyclization strategies. , 2002, Current medicinal chemistry. Anti-cancer agents.

[39]  H. Kroemer,et al.  Elucidation of the mechanism enabling tumor selective prodrug monotherapy. , 1998, Cancer research.

[40]  C. Springer,et al.  Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. , 1994, Methods and findings in experimental and clinical pharmacology.

[41]  K. D. Bagshawe,et al.  Antibody directed enzymes revive anti-cancer prodrugs concept. , 1987, British Journal of Cancer.